Tandospirone

CNS Drugs

Volumn 5, Issue 2, 1996, Pages 147-153

  Barradell, L B ^a   Fitton, A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SEROTONIN 1A RECEPTOR; TANDOSPIRONE;

ANXIETY; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; NEUROSIS; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; VERTIGO;

EID: 0030067185     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605020-00006     Document Type: Review

References (23)

1. 1. A. Hamik D. Oksenberg C. Fischette 1990 Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites Biol Psychiatry 28 99 109 1974152 10.1016/0006-3223(90)90627-E 1:CAS:528:DyaK3cXls1Ggs7c%3D Hamik A, Oksenberg D, Fischette C, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990 Jul 15; 28: 99–109
2. 2. S. Wieland C.T. Fischette I. Lucki 1993 Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors Neuropharmacology 32 561 73 8393153 10.1016/0028-3908(93)90052-5 1:CAS:528:DyaK3sXkvVGqtrY%3D Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 1993 Jun; 32: 561–73
3. 3. H. Tanaka H. Shimizu Y. Kumasaka 1991 Autoradiographic localization and pharmacological characterization of [ 3 H]tando-spirone binding sites in the rat brain Brain Res 546 2 181 9 1648988 10.1016/0006-8993(91)91479-K 1:CAS:528:DyaK3MXisVSms78%3D Tanaka H, Shimizu H, Kumasaka Y, et al. Autoradiographic localization and pharmacological characterization of [ 3 H]tando-spirone binding sites in the rat brain. Brain Res 1991; 546(2): 181–9
4. 4. H. Shimizu Y. Kumasaka H. Tanaka 1992 Anticonflict action of tandospirone in a modified Geller-Scifter conflict test in rats Jpn J Pharmacol 58 283 9 1355147 10.1254/jjp.58.283 1:CAS:528:DyaK38XitVOks78%3D Shimizu H, Kumasaka Y, Tanaka H. Anticonflict action of tandospirone in a modified Geller-Scifter conflict test in rats. Jpn J Pharmacol 1992 Mar; 58: 283–9
5. 5. H. Shimizu T. Tatsuno H. Tanaka 1992 Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test Jpn J Pharmacol 59 105 12 1354771 10.1254/jjp.59.105 1:CAS:528:DyaK38XksVSgtrk%3D Shimizu H, Tatsuno T, Tanaka H, et al. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 1992 May; 59: 105–12
6. 6. G.T. Pollard K.P. Nanry J.L. Howard 1992 Effects of tandospirone in three behavioral tests for anxiolytics Eur J Pharmacol 221 297 305 1358655 10.1016/0014-2999(92)90716-H 1:CAS:528:DyaK38XmsVGntbo%3D Pollard GT, Nanry KP, Howard JL. Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol 1992 Oct 20; 221: 297–305
7. 7. S. Wieland I. Lucki 1990 Antidepressant-like activity of 5-HT lA agonists measured with the forced swim test Psychopharmacol-ogy (Berl) 101 497 504 10.1007/BF02244228 1:CAS:528:DyaK3cXlvVCmtLo%3D Wieland S, Lucki I. Antidepressant-like activity of 5-HT lA agonists measured with the forced swim test. Psychopharmacol-ogy (Berl) 1990; 101: 497–504
8. 8. C.A. Sannerud N.A. Ator R.R. Griffiths 1993 Behavioral pharmacology of tandospirone in baboons — chronic administration and withdrawal, self-injection and drug discrimination Drug Alcohol Depend 32 195 208 8102330 10.1016/0376-8716(93)90084-4 1:CAS:528:DyaK2cXht1Cktrc%3D Sannerud CA, Ator NA, Griffiths RR. Behavioral pharmacology of tandospirone in baboons — chronic administration and withdrawal, self-injection and drug discrimination. Drug Alcohol Depend 1993 May; 32: 195–208
9. 9. H. Shimizu A. Hirose T. Tatsuno 1987 Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate Jpn J Pharmacol 45 493 500 2895201 10.1254/jjp.45.493 1:CAS:528:DyaL1cXjtFygsA%3D%3D Shimizu H, Hirose A, Tatsuno T, et al. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J Pharmacol 1987 Dec; 45: 493–500
10. 10. F. Okada Y. Torii H. Saito 1994 Antiemetic effects of serotonergic 5-HT lA-receptor agonists in Suncus murinus Jpn J Pharmacol 64 109 14 8028227 10.1254/jjp.64.109 1:CAS:528:DyaK2cXitVyntb4%3D Okada F, Torii Y, Saito H, et al. Antiemetic effects of serotonergic 5-HT lA-receptor agonists in Suncus murinus. Jpn J Pharmacol 1994 Feb;64: 109–14
11. 11. M. Nakamura S. Sugimoto H. Kurita 1992 General pharmacology of tandospirone Clin Rep 26 5 27 50 Nakamura M, Sugimoto S, Kurita H, et al. General pharmacology of tandospirone. Clin Rep 1992 May; 26(5): 27–50
12. 12. R. Tsuji Y. Ohno A. Hirose 1991 Effects of tandospirone, a 5-HT lA receptor-related anxiolytic, on the pressor response elicited by stimulation of the posterior hypothalamus in cats Arch Int Pharmacodyn Ther 311 131 43 1686389 1:CAS:528:DyaK3MXlvFyisbs%3D Tsuji R, Ohno Y, Hirose A, et al. Effects of tandospirone, a 5-HT lA receptor-related anxiolytic, on the pressor response elicited by stimulation of the posterior hypothalamus in cats. Arch Int Pharmacodyn Ther 1991 May-Jun; 311: 131–43
13. 13. S.M. Evans I.I. Troisi Jr R.R. Griffiths 1994 Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans J Pharmacol Exp Ther 271 683 94 7965783 1:CAS:528:DyaK2MXisVOqtbc%3D Evans SM, Troisi Jr II, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 1994 Nov; 271: 683–94
14. 14. M. Murasaki A. Mori S. Endo 1992 Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. A comparative double-blind study with diazepam [in Japanese Rinsho Hyoka 20 2 295 329 Murasaki M, Mori A, Endo S, et al. Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. A comparative double-blind study with diazepam [in Japanese]. Rinsho Hyoka 1992; 20(2): 295–329
15. 15. D.J. Greenblatt J.S. Harmatz M.A. Zinny 1992 Pharmacokinetics and dynamics of ascending single doses of tandospirone in healthy volunteers [abstract] J Clin Pharmacol 32 751 Greenblatt DJ, Harmatz JS, Zinny MA. Pharmacokinetics and dynamics of ascending single doses of tandospirone in healthy volunteers [abstract]. J Clin Pharmacol 1992 Aug; 32: 751
16. 16. M. Suzuki M. Uchiumi M. Murasaki 1993 Effects of tandospirone, a 5-HT lA receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam Yakubutsu Scishin Kodo 13 213 24 1:CAS:528:DyaK2cXksFSlsw%3D%3D Suzuki M, Uchiumi M, Murasaki M. Effects of tandospirone, a 5-HT lA receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Yakubutsu Scishin Kodo 1993 Aug; 13: 213–24
17. 17. N. Kikuchi U. Goto J. Suzuki 1992 Double blind study of tandospirone (SM-3997) on essential hypertension as meaning of cardiovascular psychosomatic disease: comparative study with diazepam [in Japanese Clin Rep 26 10 4351 67 Kikuchi N, Goto U, Suzuki J, et al. Double blind study of tandospirone (SM-3997) on essential hypertension as meaning of cardiovascular psychosomatic disease: comparative study with diazepam [in Japanese]. Clin Rep 1992 Sep; 26(10): 4351–67
18. 18. K.B. Oseekey S.G. Wood L.F. Chasseaud 1992 Pharmacokinetics and metabolism of tandospirone in man [abstract] Pharm Res 9 300 Oseekey KB, Wood SG, Chasseaud LF, et al. Pharmacokinetics and metabolism of tandospirone in man [abstract]. Pharm Res 1992 Oct; 9 Suppl.: 300
19. 19. M. Murasaki A. Mori S. Endo 1992 Late phase II study of a new anxiolytic, SM-3997 (tandospirone) on neurosis [in Japanese Rinsho Hyoka 20 2 259 93 Murasaki M, Mori A, Endo S, et al. Late phase II study of a new anxiolytic, SM-3997 (tandospirone) on neurosis [in Japanese]. Rinsho Hyoka 1992; 20(2): 259–93
20. 20. M. Murasaki A. Mori K. Hasegawa 1992 A clinical evaluation of anti-anxiety drug, SM-3997 (tandospirone), on various neurosis — early phase II study at Tokyo area [in Japanese Kiso to Rinsho 26 10 65 78 Murasaki M, Mori A, Hasegawa K, et al. A clinical evaluation of anti-anxiety drug, SM-3997 (tandospirone), on various neurosis — early phase II study at Tokyo area [in Japanese]. Kiso to Rinsho 1992 Sept; 26(10): 65–78
21. 21. S. Tsutsui T. Saito T. Katsura 1992 Double blind comparative study of tandospirone (SM-3997) on neurosis — placebo controlled dose-finding study Kiso to Rinsho 26 10 127 50 Tsutsui S, Saito T, Katsura T. Double blind comparative study of tandospirone (SM-3997) on neurosis — placebo controlled dose-finding study. Kiso to Rinsho 1992 Sept; 26(10): 127–50
22. 22. H. Tamai G. Komaki S. Kubota 1990 The clinical efficacy of a 5-HT lA agonist, SM-3997, in the treatment of bulimia Int J Obes 14 289 92 1971265 1:STN:280:DyaK3c3ls1elsQ%3D%3D Tamai H, Komaki G, Kubota S, et al. The clinical efficacy of a 5-HT lA agonist, SM-3997, in the treatment of bulimia. Int J Obes 1990 Mar; 14: 289–92
23. 23. M. Kimura T. Sakata T. Nakagawa 1992 Clinical evaluation of tandospirone (SM-3997), on psychosomatic diseases with gastrointestinal complaints. A comparative double-blind controlled study with diazepam and placebo [in Japanese Rinsho Hyoka 20 2 225 57 Kimura M, Sakata T, Nakagawa T, et al. Clinical evaluation of tandospirone (SM-3997), on psychosomatic diseases with gastrointestinal complaints. A comparative double-blind controlled study with diazepam and placebo [in Japanese]. Rinsho Hyoka 1992; 20(2): 225–57